Prion Diseases

Prion diseases — transmissible spongiform encephalopathies (TSEs) — are caused by the conversion of normal cellular prion protein (PrPC) into a pathologic, protease-resistant isoform (PrPSc) that templates further conversion in a self-propagating manner. The diseases are uniformly fatal, have no effective treatment, and produce distinctive neuropathologic features that have made them a paradigm of protein misfolding disease. This page covers the neuropathology of the human prion diseases and the diagnostic features that distinguish them.

The Prion Concept

Stanley Prusiner’s 1982 proposal — that an infectious agent could be “protein only” without nucleic acid — was initially controversial and is now broadly accepted. The cellular prion protein (PrPC) is a normal glycosylphosphatidylinositol-anchored membrane protein expressed widely in CNS neurons. Conversion to PrPSc involves a conformational change from a predominantly α-helical structure to one rich in β-sheets, with the misfolded protein resistant to protease digestion and able to template the same conformational change in other PrPC molecules.

Classification of Human Prion Diseases

Sporadic Forms (Most Common)

  • Sporadic Creutzfeldt-Jakob disease (sCJD): ~85% of human prion disease; ~1/million/year; mean onset 60s.
  • Sporadic fatal insomnia (sFI): rare phenocopy of FFI.

Genetic Forms

  • Familial CJD (fCJD): PRNP mutations.
  • Gerstmann-Sträussler-Scheinker (GSS): PRNP mutations; cerebellar ataxia, slower progression.
  • Fatal familial insomnia (FFI): PRNP D178N mutation; insomnia, autonomic dysfunction, motor symptoms.

Acquired Forms

  • Iatrogenic CJD: corneal transplants, dura mater grafts, growth hormone from pituitaries, neurosurgical instruments. Now rare with awareness.
  • Variant CJD (vCJD): from BSE-contaminated beef; mostly UK in 1990s-2000s.
  • Kuru: historical; ritual cannibalism (Papua New Guinea Fore people).

Sporadic Creutzfeldt-Jakob Disease (sCJD)

Clinical Features

  • Rapidly progressive dementia.
  • Myoclonus (often startle-induced).
  • Cerebellar signs.
  • Visual disturbance (Heidenhain variant — early cortical visual deficit).
  • Pyramidal/extrapyramidal signs.
  • Akinetic mutism in late stage.
  • Death usually within 6-12 months.

Diagnostic Workup

  • MRI: cortical ribbon, basal ganglia, and pulvinar/thalamic restricted diffusion. “Pulvinar sign” in vCJD; “cortical ribbon” in sCJD.
  • EEG: periodic 1 Hz sharp wave complexes (60-70% of sCJD).
  • CSF: 14-3-3 protein, neuron-specific enolase, tau elevation (supportive but not specific).
  • CSF RT-QuIC: real-time quaking-induced conversion assay — highly sensitive and specific (>90%/>99%); now the gold standard antemortem test.
  • Brain biopsy or autopsy: definitive but rarely performed antemortem.
  • PRNP gene sequencing: for genetic forms.

Pathology of CJD

  • Spongiform change: microvacuolation of gray matter neuropil; the hallmark on H&E. Vacuoles 1-50 μm in cortex, basal ganglia, thalamus, cerebellum.
  • Neuronal loss: variable but progressive.
  • Astrogliosis: marked reactive astrogliosis.
  • Microglial activation: substantial.
  • Minimal inflammation: prion disease is notably non-inflammatory.
  • PrP deposits: diffuse and synaptic; demonstrable on IHC with anti-PrP antibodies (3F4, KG9).
  • Florid plaques: characteristic of variant CJD — kuru-type plaque (dense central core with surrounding spongiform halo).
  • Distribution: cortex (random distribution), striatum, thalamus, cerebellum; brainstem variable; spinal cord usually spared.

Molecular Subtypes of sCJD

Classified by codon 129 of PRNP gene (M/V polymorphism) and PrPSc molecular type (type 1 or type 2):

  • MM1, MV1: classic sCJD — rapidly progressive dementia + myoclonus.
  • VV2, MV2: prominent cerebellar ataxia; longer course.
  • MM2, VV1: dementia-predominant or cortical variants.
  • Variably protease-sensitive prionopathy (VPSPr): rare; unique molecular features.

Variant Creutzfeldt-Jakob Disease (vCJD)

  • Caused by BSE-contaminated food in UK 1980s-90s.
  • Younger onset (mean ~28 years).
  • Psychiatric and sensory disturbance early.
  • Progressive ataxia + dementia.
  • Longer course than sCJD.
  • MRI: pulvinar sign (bilateral thalamic posterior signal).
  • Pathology: florid plaques in cortex and cerebellum + spongiform change + diffuse PrP deposits.
  • Tonsillar biopsy may show PrPSc.
  • Numbers have declined dramatically with food-chain reforms; very rare in 2026.

Fatal Familial Insomnia (FFI)

  • PRNP D178N mutation.
  • Progressive insomnia (severe, untreatable).
  • Autonomic dysfunction (sweating, hypertension, hyperthermia).
  • Motor signs (myoclonus, ataxia).
  • Cognitive decline late.
  • Pathology: selective thalamic involvement (anterior and dorsomedial nuclei) with neuronal loss and gliosis; minimal spongiform change relative to other prion diseases.

Gerstmann-Sträussler-Scheinker (GSS)

  • PRNP mutations (P102L most common, others).
  • Slower progression than sCJD (years).
  • Cerebellar ataxia predominant; cognitive decline later.
  • Pathology: multicentric amyloid plaques in cerebellum (sometimes other areas); spongiform change variable.

Kuru

Historical disease of the Fore people of Papua New Guinea, transmitted by ritual cannibalism. Pathology: cerebellar predilection with kuru plaques (PAS-positive amyloid plaques). Eradicated with cessation of the cultural practice.

Iatrogenic CJD

  • From contaminated medical materials (now mostly historical).
  • Dural grafts, corneal transplants, pituitary GH, neurosurgical instruments.
  • Incubation period: months to decades.
  • Now extremely rare with awareness and screening.

Animal Prion Diseases

  • BSE (bovine spongiform encephalopathy, “mad cow disease”): transmitted to humans as vCJD.
  • Scrapie: sheep; not known to transmit to humans.
  • Chronic wasting disease: deer, elk; concern about human transmission (no proven cases to date but surveillance ongoing).

Practical Considerations

Infection Control

Standard chemical sterilization (autoclaving) does NOT inactivate prions. Special protocols required:

  • Surgical instruments used on suspected prion cases require dedicated handling or destruction.
  • Brain biopsy of suspected CJD requires special precautions.
  • Health workers handling brain tissue use full PPE.

Family Counseling

  • Genetic forms: family screening considered.
  • Sporadic and iatrogenic: not transmissible in normal human contact.

Differential Diagnosis of Rapidly Progressive Dementia

CJD is THE classic cause of rapidly progressive dementia, but the differential includes:

  • Autoimmune encephalitis (LGI1, anti-NMDA, etc.) — treatable.
  • Hashimoto encephalopathy.
  • Vasculitis.
  • Neurosyphilis.
  • Wernicke encephalopathy.
  • Aggressive frontotemporal dementia variants.
  • Atypical Alzheimer (rare).
  • Late-onset Tay-Sachs (very rare in adults).
  • Lymphomatosis cerebri.
  • Toxic-metabolic.

Always work up rapidly progressive dementia for treatable mimics before committing to a prion diagnosis. RT-QuIC has dramatically improved antemortem confidence.

🔍 Did You Know?

The development of real-time quaking-induced conversion (RT-QuIC) testing has revolutionized the antemortem diagnosis of prion disease. The assay exploits the templating ability of PrPSc: a small amount of patient CSF is added to a reaction containing recombinant PrP and a fluorescent dye that binds amyloid β-sheets. If any PrPSc is present, it seeds conversion of the recombinant PrP into amyloid fibrils, which the dye detects with progressively increasing fluorescence as the reaction is repeatedly agitated (quaked). The result: a sensitive (>90%) and highly specific (>99%) test for prion disease in CSF — finally allowing confident antemortem diagnosis in many patients. Before RT-QuIC, the antemortem workup relied on supportive but non-specific findings (14-3-3 protein, MRI cortical ribbon, EEG periodic complexes), and definitive diagnosis required tissue. The RT-QuIC era means patients and families can be told the diagnosis with high confidence while the patient is still alive, enabling end-of-life planning, family counseling, and exclusion of treatable mimics with much greater certainty. The technique was developed in the early 2010s by the NIH and rapidly entered clinical practice. The lesson: for any patient with rapidly progressive dementia and possible prion disease, RT-QuIC should be ordered alongside the autoimmune encephalitis antibody panel — together they identify both the prion disease and the treatable mimics with confidence that was impossible a decade ago.

Pitfalls and Pearls

  • Spongiform change: hallmark of CJD; microvacuolation of neuropil.
  • Sporadic CJD: rapidly progressive dementia + myoclonus + cerebellar / pyramidal / extrapyramidal + visual.
  • MRI cortical ribbon + basal ganglia DWI: sCJD.
  • Pulvinar sign: variant CJD (now rare).
  • EEG periodic complexes: sCJD (60-70%); not all cases.
  • CSF RT-QuIC: highly sensitive and specific antemortem test for prion disease.
  • 14-3-3, tau, NSE: supportive but not specific for CJD.
  • FFI: progressive insomnia + autonomic + selective thalamic involvement; PRNP D178N.
  • GSS: cerebellar ataxia + multicentric amyloid plaques.
  • vCJD florid plaques: distinctive (dense core + spongiform halo).
  • Always rule out treatable mimics: autoimmune encephalitis (LGI1, anti-NMDA), Hashimoto, vasculitis, Wernicke.
  • Iatrogenic transmission: dural grafts, GH, contaminated instruments; preventable.
  • Prions resist autoclaving; special infection control required.
  • Heidenhain variant CJD: cortical visual deficit + rapid dementia.
  • RT-QuIC has changed antemortem diagnosis — now the gold standard.

References

  1. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216(4542):136-144.
  2. Ironside JW, Ritchie DL, Head MW. Prion diseases. Handb Clin Neurol. 2017;145:393-403.
  3. Atarashi R, Sano K, Satoh K, Nishida N. Real-time quaking-induced conversion: a highly sensitive assay for prion detection. Prion. 2011;5(3):150-153.
  4. Foutz A, Appleby BS, Hamlin C, et al. Diagnostic and prognostic value of human prion detection in cerebrospinal fluid. Ann Neurol. 2017;81(1):79-92.
  5. Geschwind MD. Prion diseases. Continuum (Minneap Minn). 2015;21(6):1612-1638.
  6. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347(9006):921-925.